First Patient Dosed with Hemophilia Gene Therapy Candidate ASC618

The first patient has been dosed in ASC Therapeutics clinical trial of ASC618, the company’s investigational AAV8 vector-based gene therapy for patients with severe and moderately severe hemophilia A.

Source: National Bleeding Disorders Foundation, December 2023